Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
REDWOOD CITY, Calif., Feb. 02, 2016 -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016 at 1:00 p.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at http://investor.relypsa.com/events.cfm.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Alex Dobbin
Associate Director, Investor Relations
650-421-9687
[email protected]
